Trending...
- Friendly Pro Services Helps Metro Detroit Homeowners Prepare for Changing Seasons, Power Outages and Winter Weather
- Sky Quarry Restarts Nevada's Only Crude Oil Refinery — A Major New Chapter Begins in This Highly Lucrative sector for N A S D A Q: SKYQ
- Radio Drive's New Album Walk With Me Delivers Two GRAMMY® Submissions Across Rock and Alternative Categories
Contact: Ryan Jarvi 517-599-2746Agency: Attorney General
November 17, 2020
LANSING — Michigan Attorney General Dana Nessel joined a coalition of 22 attorneys general in a letter to the U.S. Department of Health & Human Services (HHS) and its National Institutes of Health (NIH) urging them to reject recent recommendations made by the Trump administration's NIH Human Fetal Tissue Ethics Advisory Board (Board).
The Board's recommendation would withhold federal funding for fetal tissue research grant proposals, putting limits on research into possible treatments and therapies for various health conditions, including COVID-19. The recommendation comes after a two-year campaign by the Trump administration to block federally funded research using fetal tissue as well as an executive order to ban the research.
"While leading scientists are encouraging the use of fetal tissue research to develop treatments for the COVID-19 pandemic, the Trump administration is attempting to withhold critical funding for this important work," Nessel said. "Our country has been hard hit by this pandemic – this recommendation by the Board would effectively hinder advances in finding a treatment for this devastating virus. President Trump himself was treated for COVID with Remdesivir, a drug developed through fetal tissue research – why shouldn't every American have that opportunity?"
More on Michimich.com
Fetal tissue has been an essential part of scientific and medical advances that have saved millions of lives in the United States and across the globe. Fetal tissue was used in the research that led to the vaccines for poliovirus, rubella, measles and rabies. It remains a crucial part of vital biomedical research.
In its letter, the coalition argues the Board was not fairly balanced in terms of viewpoint, as two-thirds of its members are on record opposing abortion, fetal tissue or both. The Board's proceedings also lacked transparency. All of its meetings were in closed session except for one virtual meeting held for less than an hour. The attorneys general urge NIH Director Francis S. Collins and HHS Secretary Alex M. Azar II to use their authority to reject the Board's recommendations and maintain federal funding for research projects using fetal tissue that have already been recommended for funding.
In sending the letter, Attorney General Nessel joins the attorneys general of California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Iowa, Maine, Maryland, Massachusetts, Minnesota, Nevada, New Jersey, New Mexico, New York, Oregon, Rhode Island, Vermont, Virginia, Wisconsin, and the District of Columbia.
A copy of the letter is available here.
November 17, 2020
LANSING — Michigan Attorney General Dana Nessel joined a coalition of 22 attorneys general in a letter to the U.S. Department of Health & Human Services (HHS) and its National Institutes of Health (NIH) urging them to reject recent recommendations made by the Trump administration's NIH Human Fetal Tissue Ethics Advisory Board (Board).
The Board's recommendation would withhold federal funding for fetal tissue research grant proposals, putting limits on research into possible treatments and therapies for various health conditions, including COVID-19. The recommendation comes after a two-year campaign by the Trump administration to block federally funded research using fetal tissue as well as an executive order to ban the research.
"While leading scientists are encouraging the use of fetal tissue research to develop treatments for the COVID-19 pandemic, the Trump administration is attempting to withhold critical funding for this important work," Nessel said. "Our country has been hard hit by this pandemic – this recommendation by the Board would effectively hinder advances in finding a treatment for this devastating virus. President Trump himself was treated for COVID with Remdesivir, a drug developed through fetal tissue research – why shouldn't every American have that opportunity?"
More on Michimich.com
- Dr. Jay Johannigman Returns to Cincinnati Following 46 Years of Military Service
- Allstream Energy Partners, SEO Experts in Oil and Gas, Awarded Gas Processing OEM Agreement
- Growth Story Expands: $54.6M Contract, $30M Revenue Run Rate, 800+ Customers, 50+ Patents & New AI Cybersecurity Products for Cycurion, Inc $CYCU
- Sky Quarry Restarts Nevada's Only Crude Oil Refinery — A Major New Chapter Begins in This Highly Lucrative sector for N A S D A Q: SKYQ
- Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
Fetal tissue has been an essential part of scientific and medical advances that have saved millions of lives in the United States and across the globe. Fetal tissue was used in the research that led to the vaccines for poliovirus, rubella, measles and rabies. It remains a crucial part of vital biomedical research.
In its letter, the coalition argues the Board was not fairly balanced in terms of viewpoint, as two-thirds of its members are on record opposing abortion, fetal tissue or both. The Board's proceedings also lacked transparency. All of its meetings were in closed session except for one virtual meeting held for less than an hour. The attorneys general urge NIH Director Francis S. Collins and HHS Secretary Alex M. Azar II to use their authority to reject the Board's recommendations and maintain federal funding for research projects using fetal tissue that have already been recommended for funding.
In sending the letter, Attorney General Nessel joins the attorneys general of California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Iowa, Maine, Maryland, Massachusetts, Minnesota, Nevada, New Jersey, New Mexico, New York, Oregon, Rhode Island, Vermont, Virginia, Wisconsin, and the District of Columbia.
A copy of the letter is available here.
0 Comments
Latest on Michimich.com
- Save 15 Percent Off Florida Keys Accommodations with KeysCaribbean's Advance Purchase Rate Discount
- Woodside Rehab & Nursing Enters a New Era of Clinical Excellence and Growth
- Thar Process Partners with French Leader ExtrateX to Bring Prep to Process-Scale SFC to Europe
- Port St. Lucie REALTOR® Irene Pernice Earns SFR® Certification
- AMR and UAS Take the Stage at WorldSkills Shanghai 2026
- Biophysical Therapeutics brings longevity science to skincare with its new IF1 brand
- JoCa's Echoes of Haworth Sells Out on Opening Night in Mexico City; Artist Heads to San Luis Potosí and Miami Art Week
- Home2 Suites by Hilton Lee's Summit, MO Opens to Guests
- Shanghai Chengwei Semiconductor Equipment Launches High Precision Laboratory Central Gas Supply System
- Your Local Pro Expands National Service Network to 273+ Locations Across Plumbing, Cleaning, Landscaping and Hydrovac
- Acuvance Coker Study Finds Experience, Not Supply, Is the Biggest Advanced Practice Provider Workforce Challenge
- Uk Financial Moonshot Token™ Robinhood-chain Goes Live On Tokpie Exchange Tomorrow, With Solana Side Of UKFLMS To Follow In Global Listing Expansion
- We're Not Too Hungry for Love. We May Be Feeding the Hunger the Wrong Things
- Ann Arbor-Based Socius Earns Odoo Silver Partner Status
- Friendly Pro Services Helps Metro Detroit Homeowners Prepare for Changing Seasons, Power Outages and Winter Weather
- Solid Earth's new "Welcome to Real Estate" campaign introduces RealtyID™: Know Before Your Open the Door
- Radio Drive's New Album Walk With Me Delivers Two GRAMMY® Submissions Across Rock and Alternative Categories
- Kaplan Morrell and Attorney Jacqui Condon Selected to Represent Professional Women's Soccer Players in Workers' Compensation Matters
- ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
- Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement